PTC Therapeutics stock gets a Fabry therapy catalyst

PTC Therapeutics stock was trading at USD 61.99 on Nasdaq on September 24, 2026, down 0.56 percent from the previous close of USD 62.34. The company completed its acquisition of ST-920, a late-stage gene therapy candidate for Fabry disease, on September 21, 2026.

ST-920 adds a late-stage asset

In its September 21 release, PTC Therapeutics said ST-920 is a one-time administered AAV therapy with a rolling biologics license application submission expected in Q4 2026. The acquisition adds a regulatory-stage program to a portfolio that already spans marketed rare-disease medicines and clinical candidates.

The transaction terms give the strategy a measurable financial boundary. Investing.com reported on September 22 that PTC agreed to pay USD 111 million upfront plus up to USD 100 million in regulatory milestone payments. Cantor Fitzgerald raised its price target from USD 130 to USD 137 and maintained an Overweight rating.

Q2 results reset the baseline

PTC's fiscal Q2 2026 revenue was USD 360.52 million, up 101.5 percent year over year and above the USD 298.63 million consensus estimate, according to Trefis. Adjusted EPS was USD 0.92 versus USD 0.24 expected, a USD 0.68 beat.

The same Q2 2026 update listed full-year revenue guidance of USD 1.18 billion to USD 1.28 billion, compared with prior guidance of USD 1.13 billion. That combination of operating scale and pipeline investment gives the market two separate benchmarks: near-term product execution and the eventual regulatory value of ST-920.

Stock remains below yearly high

At USD 61.99 on September 24, 2026, PTC Therapeutics had a market capitalization of USD 5,173,760,030 and traded 31.78 percent below its 52-week high of USD 90.87. The current session therefore values the company well below its yearly peak while investors assess the cost and timing of the Fabry program.